Almirall announces pricing of €300 Million in the issuance of senior notes due 2026

BARCELONA, Spain. September 16, 2021 – Almirall S.A. (BME: ALM), a global biopharmaceutical company focused on skin health, announces that it has successfully completed the pricing of the issuance of senior notes in an aggregate principal amount of €300 million due 2026. The Notes are offered only to qualified institutional buyers, in accordance with Rule 144A under the United States Securities Act of 1933, as amended (the “Securities Act”), and to non-US persons outside the United States in accordance with Regulation S under the Securities Act.

The Notes will bear an annual interest of 2.125%, payable semi-annually. The closing of the issuance and payment of the Notes is expected to take place on or about September 22, 2021, subject to compliance with certain conditions precedent customary for transactions of this nature.

The proceeds from the issuance of the Notes will be used: (i) at their maturity, to repay in full and cancel the Company’s €250,000,000 aggregate principal amount of 0.250% senior unsecured conditionally convertible bonds due December 14, 2021, including accrued and unpaid interest; (ii) to pay transaction fees and expenses; and (iii) for general corporate purposes.

The pharmaceutical company also announced that the agencies “Standard & Poor’s” and “Moody’s” have issued their respective ratings with regard to the issuer entity, Almirall, and the Notes. “Standard & Poor’s has assigned corporate rating (BB-) and Notes rating (BB-); and “Moody’s” has assigned corporate rating (Ba3) and Notes rating (Ba3).

About Almirall

Almirall is a global biopharmaceutical company focused on skin health. We collaborate with scientists and healthcare professionals to address patient’s needs through science to improve their lives. Our Noble Purpose is at the core of our work: “Transform the patients' world by helping them realize their hopes and dreams for a healthy life”. We invest in differentiated and ground-breaking medical dermatology products to bring our innovative solutions to patients in need.

The company, founded in 1943 and headquartered in Barcelona, is publicly traded on the Spanish Stock Exchange and is a member of the IBEX35 (ticker: ALM). Throughout its 77-year history, Almirall has retained a strong focus on the needs of patients. Currently, Almirall has a direct presence in 21 countries and strategic agreements in over 70, through 13 subsidiaries, with about 1,800 employees. Total revenues in 2020 were 814.5 million euros.

For more information, please visit almirall.com